You are here

Article Text

Article menu
Download PDFPDF
Abstracts from the 15th Congress of the European Society for Developmental, Perinatal and Paediatric Pharmacology, held in Belgrade, June 2015.
POSTER PRESENTATIONS
PP 058
FLUOROQUINOLONES IN PEDIATRIC PATIENTS: NO MORE “OFF-LABEL USE”
  1. Natalie Dinavitser1,
  2. Maya Berlin1,
  3. Reuven Miller2,
  4. Victoriya Finkel-Pekarsky3,
  5. Matitiahu Berkovitch1
  1. 1Clinical Pharmacology Unit, Assaf Harofeh Medical Center, Zerifin, Sackler School of Medicine, Tel-Aviv University
  2. 2Pharmacovigilance and Drug Information Department, Pharmaceutical Division, Ministry of Health, Jerusalem
  3. 3Regulatory Affairs Department, Pharmaceutical Division, Ministry of Health, Pharmaceutical Division, Ministry of Health, Jerusalem

Abstract

Fluoroquinolones (FQs) are used in pediatric patients worldwide. However, due to cartilage damage in young animals they are not approved for children under 18 years of age for most indications. Major regulatory authorities such as EMA, FDA, UK, Ireland, NZ and Australia indicate that FQs are contraindicated in children. Ciprofloxacin and levofloxacin can be prescribed to children, but only for a few indications. As a result, FQs are used “off-label” in this population. From our experience, we believe that FQs should not be contraindicated in children. However, evidence-based data is needed.

Objective To investigate whether FQ use in children may cause musculoskeletal adverse reactions (ADRs).

Methods We reviewed the Israel Ministry of Health ADR reporting system and VigiLyze (WHO reporting system) for musculoskeletal ADRs due to FQs in children. A literature search– Medline, Pubmed, Cochraine database and pharmacologic textbooks, for musculoskeletal ADRs among FQ treated pediatric patients was conducted. Terms used: Fluoroquinolones, ciprofloxacin, levofloxacin, ofloxacin, arthropathy, tendinophaty, arthralgia, children, pediatric use.

Results During the period 1968 to Feb 2015, the Israeli MOH did not receive spontaneous reports regarding FQs in children. The VigiLyze program identified 192 ADR reports in children related to FQs: arthralgia, arthropathy, myalgia, and tendon injury. Most ADRs were transient and reversible. The literature search indicated that although musculoskeletal ADRs are not uncommon, they are mild, transient, and not necessarily due to FQs. Joint MRI, performed in some of the studies, did not reveal cartilage damage.

Conclusions FQs should be registered for pediatric patients as for adults.

  • ESDP

https://doi.org/10.1136/archdischild-2015-310148.58

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.